UY26970A1 - Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos - Google Patents
Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivosInfo
- Publication number
- UY26970A1 UY26970A1 UY26970A UY26970A UY26970A1 UY 26970 A1 UY26970 A1 UY 26970A1 UY 26970 A UY26970 A UY 26970A UY 26970 A UY26970 A UY 26970A UY 26970 A1 UY26970 A1 UY 26970A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- acetilcolinesterase
- gaba
- agonists
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Esta invención proporciona una composición para el tratamiento de un trastorno cognitivo, que comprende un inhibidor de acetilcolinesterasa y un agonista inverso de GABA, seleccionado entre un compuesto de fórmula I en el aque X e Y son como se definen en este documento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24114500P | 2000-10-17 | 2000-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26970A1 true UY26970A1 (es) | 2002-06-20 |
Family
ID=22909428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26970A UY26970A1 (es) | 2000-10-17 | 2001-10-16 | Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos |
Country Status (14)
Country | Link |
---|---|
US (2) | US20020151591A1 (es) |
EP (1) | EP1328294A2 (es) |
JP (1) | JP2004511512A (es) |
KR (1) | KR20030046509A (es) |
AR (1) | AR030893A1 (es) |
AU (2) | AU2001294117B2 (es) |
CA (1) | CA2426120A1 (es) |
HU (1) | HUP0302476A3 (es) |
IL (1) | IL155225A0 (es) |
NZ (1) | NZ525103A (es) |
PE (1) | PE20020473A1 (es) |
UY (1) | UY26970A1 (es) |
WO (1) | WO2002032412A2 (es) |
ZA (1) | ZA200302918B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
NZ541282A (en) * | 2002-12-24 | 2009-02-28 | Bellus Health International Ltd | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
JPWO2005027968A1 (ja) * | 2003-09-19 | 2007-11-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ダウン症候群治療剤 |
TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
EP1750724A4 (en) * | 2004-05-14 | 2008-01-23 | Univ Johns Hopkins | METHOD FOR ENHANCING COGNITIVE FUNCTION USING CO-ADMINISTRATION OF GABAB RECEPTOR ANTAGONIST AND ACETYLCHOLINESTERASE INHIBITOR |
BRPI0513386A (pt) * | 2004-08-09 | 2008-05-06 | Warner Lambert Co | inibidores de reabsorção de norepinefrina de quinoxalinona para o tratamento de distúrbios do sistema nervoso central |
CN100382802C (zh) * | 2005-08-08 | 2008-04-23 | 赵德禄 | 治疗自主神经系统功能紊乱的药物 |
EP3050562A1 (en) | 2006-05-22 | 2016-08-03 | The Board of Trustees of the Leland Stanford Junior University | Pharmacological treatment of cognitive impairment using gabaa receptor antagonists |
US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
WO2008046135A1 (en) | 2006-10-16 | 2008-04-24 | Bionomics Limited | Novel anxiolytic compounds |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
CN102905532A (zh) | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
EA027840B1 (ru) | 2010-11-15 | 2017-09-29 | Эйджинбайо, Инк. | Производные пиридазина, композиции и способы лечения когнитивного нарушения |
US9023848B2 (en) | 2011-03-02 | 2015-05-05 | Bionomics Limited | Small-molecules as therapeutics |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
AU2012253237B2 (en) | 2011-05-12 | 2015-09-24 | Bionomics Limited | Methods for preparing naphthyridines |
US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
ES2881081T3 (es) | 2013-03-15 | 2021-11-26 | Agenebio Inc | Procedimientos y composiciones para mejorar la función cognitiva |
CA3123897C (en) | 2013-12-20 | 2024-02-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
MX2017014774A (es) | 2015-05-22 | 2018-02-15 | Agenebio Inc | Composiciones farmaceuticas de levetiracetam de liberacion extendida. |
CN108026107B (zh) | 2015-06-19 | 2021-07-30 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
EA202190076A1 (ru) | 2018-06-19 | 2021-09-22 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений |
WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
US5870723A (en) * | 1994-11-28 | 1999-02-09 | Pare, Jr.; David Ferrin | Tokenless biometric transaction authorization method and system |
US6088683A (en) * | 1996-08-21 | 2000-07-11 | Jalili; Reza | Secure purchase transaction method using telephone number |
US6016476A (en) * | 1997-08-11 | 2000-01-18 | International Business Machines Corporation | Portable information and transaction processing system and method utilizing biometric authorization and digital certificate security |
PL338783A1 (en) * | 1997-08-25 | 2000-11-20 | Neurogen Corp | Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors |
US6143760A (en) * | 1997-08-25 | 2000-11-07 | Neurogen Corporation | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands |
GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
-
2001
- 2001-10-12 US US09/976,347 patent/US20020151591A1/en not_active Abandoned
- 2001-10-15 NZ NZ52510301A patent/NZ525103A/xx unknown
- 2001-10-15 AU AU2001294117A patent/AU2001294117B2/en not_active Ceased
- 2001-10-15 HU HU0302476A patent/HUP0302476A3/hu unknown
- 2001-10-15 EP EP01974604A patent/EP1328294A2/en not_active Withdrawn
- 2001-10-15 CA CA002426120A patent/CA2426120A1/en not_active Abandoned
- 2001-10-15 AR ARP010104836A patent/AR030893A1/es unknown
- 2001-10-15 KR KR10-2003-7005292A patent/KR20030046509A/ko not_active Application Discontinuation
- 2001-10-15 WO PCT/IB2001/001934 patent/WO2002032412A2/en active IP Right Grant
- 2001-10-15 JP JP2002535650A patent/JP2004511512A/ja active Pending
- 2001-10-15 IL IL15522501A patent/IL155225A0/xx unknown
- 2001-10-15 AU AU9411701A patent/AU9411701A/xx active Pending
- 2001-10-16 UY UY26970A patent/UY26970A1/es not_active Application Discontinuation
- 2001-10-16 PE PE2001001026A patent/PE20020473A1/es not_active Application Discontinuation
-
2003
- 2003-04-11 ZA ZA200302918A patent/ZA200302918B/en unknown
-
2004
- 2004-08-06 US US10/912,993 patent/US20050009861A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2001294117B2 (en) | 2006-07-27 |
WO2002032412A2 (en) | 2002-04-25 |
IL155225A0 (en) | 2003-11-23 |
NZ525103A (en) | 2004-12-24 |
AR030893A1 (es) | 2003-09-03 |
US20020151591A1 (en) | 2002-10-17 |
WO2002032412A3 (en) | 2003-03-20 |
PE20020473A1 (es) | 2002-06-14 |
KR20030046509A (ko) | 2003-06-12 |
ZA200302918B (en) | 2004-04-13 |
AU9411701A (en) | 2002-04-29 |
EP1328294A2 (en) | 2003-07-23 |
JP2004511512A (ja) | 2004-04-15 |
HUP0302476A2 (hu) | 2003-11-28 |
CA2426120A1 (en) | 2002-04-25 |
US20050009861A1 (en) | 2005-01-13 |
HUP0302476A3 (en) | 2005-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26970A1 (es) | Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos | |
ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
NO20024221D0 (no) | Blandinger inneholdende alfa-2-adrenerge agonistkomponenter | |
ECSP034492A (es) | Derivados de hidroxamato utiles como inhibidores de desacetilasa | |
CR9772A (es) | Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos | |
ATE512151T1 (de) | Pyrrolotriazin-kinaseinhibitoren | |
DE602005014382D1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren | |
ATE420879T1 (de) | Indolizine als kinaseproteinhemmer | |
CR9244A (es) | AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA | |
PE20021015A1 (es) | Compuestos inhibidores de tirosina cinasa | |
AR026173A1 (es) | Inhibidores de neuraminidasas. | |
ECSP034750A (es) | Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
PA8567001A1 (es) | Composicion de ziprasidona y controles sinteticos | |
UY29479A1 (es) | Inhibidores de adn-pk | |
EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
CR7332A (es) | INHIBIDORES DEL FACTOR Xa Y DE OTRAS PROTEASAS DE SERINA IMPLICADAS EN LA CASCADA DE LA COAGULACION | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
MX2007002383A (es) | Composiciones que contienen componentes agonistas alfa-2-adrenergicos. | |
ES2571730T3 (es) | Composiciones farmacéuticas que comprenden droxidopa | |
ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
ECSP077426A (es) | USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO | |
UA85505C2 (en) | Kinase inhibitors | |
CL2007002381A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis | |
HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
UY28925A1 (es) | Nuevos derivados de aminopiridina y su uso como fármacos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150429 |